CGTX - Cognition Therapeutics to Report Fourth Quarter and Full Year 2023 Results | Benzinga
PURCHASE, N.Y., March 15, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ:CGTX), a clinical-stage neuroscience company developing product candidates designed to treat neurodegenerative disorders by regulating cellular damage response pathways, today announced that the Company will release financial results for the fourth quarter and full year ended December 31, 2023 on Tuesday, March 26, 2024 before the market open. Following the release, management will host a conference call at 8:00 a.m. ET on the same day to review the financial and operating results and provide a business update.
Conference Call Information:
| Telephone Access: |
| US/Canada Participant Toll-Free Dial-in Number: (800) 715-9871 US/Canada Participant International Dial-In Number: (646) 307-1963 Conference ID Number: 6295507 |
| Webcast Access: |
| The audio webcast with live Q&A will be accessible at https://edge.media-server.com/mmc/p/q7djwfy4 or via the Investor Relations section of Cognition's website. An archive of the webcast and presentation will be available for 90 days beginning at approximately 10:00 a.m. ET on March 26, 2024. |
About Cognition Therapeutics:
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. We are currently investigating our lead candidate CT1812 in clinical programs in Alzheimer's disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD). We believe CT1812 and our pipeline of ?-2 receptor modulators can regulate pathways that are impaired in these diseases. We believe that ...